<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284114</url>
  </required_header>
  <id_info>
    <org_study_id>JMU-N1</org_study_id>
    <nct_id>NCT01284114</nct_id>
  </id_info>
  <brief_title>Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients</brief_title>
  <official_title>Effects of Aliskiren on Blood Pressure, Heart and Kidney in Elderly Hypertensive Chronic Kidney Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jichi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jichi Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether aliskiren is effective in the treatment of
      blood pressure, hear function, renal function in elderly hypertensive chronic kidney disease
      (CKD) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease (CKD) was reported to be affecting 11% of the all population. This
      number is much higher in the elderly population and may be as high as 30%. CKD is an
      independent risk factor of cardiovascular disease (CVD). This is called &quot;Cardio-renal
      Continuum&quot;. The renin-angiotensin-aldosterone system (RAS) plays pivotal roles in both
      cardiovascular and renal functions.

      The increased oxidative stress by activated RAS on vascular endothelium is one of important
      factor to development of Cardio-renal Continuum. The blockade of RAS by angiotensin I
      converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) has been
      reported to ameliorate the renal disease and CVD; however,they do not completely suppress
      RAS, leading to a reactive rise in plasma renin activity (PRA). Aliskiren, an oral direct
      renin inhibitor, is effective against essential hypertension by reducing PRA, resulting in
      more complete suppression of RAS; however, little is known about the effects of aliskiren on
      heart and kidney functions in elderly hypertensive CKD patients. In this study, we assessed
      the efficacy of aliskiren on heart and kidney functions in elderly hypertensive CKD patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change of Blood Pressure</measure>
    <time_frame>baseline and 6 month</time_frame>
    <description>The change of systolic blood pressure and diastolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change of Heart Function Confirmed by Echocardiograph</measure>
    <time_frame>baseline and 6 month</time_frame>
    <description>Left ventricular ejection fraction (LVEF)were measured by echocardiogram at baseline and 6 month. Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change of BNP</measure>
    <time_frame>baseline and 6month</time_frame>
    <description>Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change of eGFR</measure>
    <time_frame>baseline and 6 month</time_frame>
    <description>eGFR was calculated at baseline and at 6 month using a modified version of the Modification of Diet in Renal Disease (MDRD) formula of the Japanese Society of Nephrology as follows: eGFR (ml/min/1.73 m2) = 194 × age-0.287 × serum creatinine-1.094 (multiplied by 0.739 for females).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change of Urine Albumin/ Creatinine Ratio (UACR).</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>The UACR was measured at baseline, Week12 and Week24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change of Oxidative Stress Markers Confirmed by Plasma Level of 8-OHdG and d-ROM</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hypertension</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Direct renin inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Chronic kidney disease

          -  Clinical diagnosis of Hypertension (Blood pressure &gt;=140/90mmHg)

          -  Elderly people(&gt;=65 years old)

        Exclusion Criteria:

          -  The patients who are already taking aliskiren

          -  The patients who are receiving hemodialysis or peritoneal dialysis

          -  The patients who are taking cyclosporin

          -  The patients who have hyperkalemia(&gt;=5.5mEq/ml)

          -  Severe heart failure (&gt;=NYHA class III)

          -  Insulin dependent diabetic mellitus or poor controlled insulin independent diabetic
             mellitus (&gt;=HbA1c 9.0&amp;)

          -  Severe liver dysfunction (five folds increased AST or ALT than standard values)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshiyuki Morishita, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Department of Medicine, Jichi Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Niimi city Yukawa National health insurance clinic</name>
      <address>
        <city>Niimi</city>
        <state>Okayama</state>
        <zip>719-2643</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konan Hospital</name>
      <address>
        <city>Oyama</city>
        <state>Tochigi</state>
        <zip>329-0214</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurosu Hospital</name>
      <address>
        <city>Sakura</city>
        <state>Tochigi</state>
        <zip>329-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>3290498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res. 2011 Mar;34(3):308-13. doi: 10.1038/hr.2010.238. Epub 2010 Dec 2.</citation>
    <PMID>21124333</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2011</study_first_posted>
  <results_first_submitted>July 5, 2012</results_first_submitted>
  <results_first_submitted_qc>September 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2012</results_first_posted>
  <last_update_submitted>September 19, 2012</last_update_submitted>
  <last_update_submitted_qc>September 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jichi Medical University</investigator_affiliation>
    <investigator_full_name>Yoshiyuki Morishita</investigator_full_name>
    <investigator_title>MD. PhD</investigator_title>
  </responsible_party>
  <keyword>Elderly chronic kidney disease</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Aliskiren</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between February 2011 and December 2011 in Tochigi prefecture and Okayama prefecture in Japan</recruitment_details>
      <pre_assignment_details>4 week observation period to fix any drugs, including existing antihypertensives</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>Aliskiren: This group recived aliskiren at 150mg orally in the morning once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>viral infection</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>From the results of ALLTITUDE study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Symptomatic hypotension</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>dizziness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change of Blood Pressure</title>
        <description>The change of systolic blood pressure and diastolic blood pressure</description>
        <time_frame>baseline and 6 month</time_frame>
        <population>We analyzed all patients who completed study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
          </group>
        </group_list>
        <measure>
          <title>The Change of Blood Pressure</title>
          <description>The change of systolic blood pressure and diastolic blood pressure</description>
          <population>We analyzed all patients who completed study.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change of Heart Function Confirmed by Echocardiograph</title>
        <description>Left ventricular ejection fraction (LVEF)were measured by echocardiogram at baseline and 6 month. Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month.</description>
        <time_frame>baseline and 6 month</time_frame>
        <population>We analyzed participants who copmleted this study</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
          </group>
        </group_list>
        <measure>
          <title>The Change of Heart Function Confirmed by Echocardiograph</title>
          <description>Left ventricular ejection fraction (LVEF)were measured by echocardiogram at baseline and 6 month. Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month.</description>
          <population>We analyzed participants who copmleted this study</population>
          <units>% of stroke vulume/enddiastolic volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="-1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change of BNP</title>
        <description>Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month.</description>
        <time_frame>baseline and 6month</time_frame>
        <population>We analyzed all patients who completed study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren: This group recived aliskiren at 150mg orally in the morning once daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Change of BNP</title>
          <description>Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month.</description>
          <population>We analyzed all patients who completed study.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="-4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change of Oxidative Stress Markers Confirmed by Plasma Level of 8-OHdG and d-ROM</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change of eGFR</title>
        <description>eGFR was calculated at baseline and at 6 month using a modified version of the Modification of Diet in Renal Disease (MDRD) formula of the Japanese Society of Nephrology as follows: eGFR (ml/min/1.73 m2) = 194 × age-0.287 × serum creatinine-1.094 (multiplied by 0.739 for females).</description>
        <time_frame>baseline and 6 month</time_frame>
        <population>We analyzed all patients who completed study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren: This group recived aliskiren at 150mg orally in the morning once daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Change of eGFR</title>
          <description>eGFR was calculated at baseline and at 6 month using a modified version of the Modification of Diet in Renal Disease (MDRD) formula of the Japanese Society of Nephrology as follows: eGFR (ml/min/1.73 m2) = 194 × age-0.287 × serum creatinine-1.094 (multiplied by 0.739 for females).</description>
          <population>We analyzed all patients who completed study.</population>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change of Urine Albumin/ Creatinine Ratio (UACR).</title>
        <description>The UACR was measured at baseline, Week12 and Week24</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>We analyzed all patients who completed this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
          </group>
        </group_list>
        <measure>
          <title>The Change of Urine Albumin/ Creatinine Ratio (UACR).</title>
          <description>The UACR was measured at baseline, Week12 and Week24</description>
          <population>We analyzed all patients who completed this study.</population>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-337.5" spread="-484.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yoshiyuki Morishita</name_or_title>
      <organization>Division of Nephrology, Department of Internal Medicine, Jichi Medical University</organization>
      <phone>81-285-58-7346</phone>
      <email>ymori@jichi.ac.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

